Compare · ABBV vs APRE
ABBV vs APRE
Side-by-side comparison of AbbVie Inc. (ABBV) and Aprea Therapeutics Inc. (APRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and APRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $406.38B, about 41353.5x APRE ($9.8M).
- Over the past year, ABBV is up 27.9% and APRE is down 49.0% - ABBV leads by 76.9 points.
- ABBV has been more active in the news (14 items in the past 4 weeks vs 11 for APRE).
- ABBV has more recent analyst coverage (25 ratings vs 5 for APRE).
- Company
- AbbVie Inc.
- Aprea Therapeutics Inc.
- Price
- $234.88+2.11%
- $0.85+8.02%
- Market cap
- $406.38B
- $9.8M
- 1M return
- +9.46%
- -8.20%
- 1Y return
- +27.86%
- -49.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2019
- News (4w)
- 14
- 11
- Recent ratings
- 25
- 5
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Aprea Therapeutics Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
- AbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
- AbbVie Declares Quarterly Dividend
- Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
- FDA Approval for SKYRIZI issued to ABBVIE INC
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest APRE
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
- Director Grissinger Michael was granted 3,135 shares, increasing direct ownership by 109% to 6,024 units (SEC Form 4)
- Director Gruia Gabriela was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)
- Director Peters Richard was granted 3,135 shares, increasing direct ownership by 101% to 6,254 units (SEC Form 4)
- Director Henneman John B Iii was granted 3,135 shares, increasing direct ownership by 31% to 13,364 units (SEC Form 4)
- Director Bizzari Jean-Pierre was granted 3,135 shares, increasing direct ownership by 300% to 4,180 units (SEC Form 4)
- Director Duey Marc was granted 3,135 shares, increasing direct ownership by 1% to 259,290 units (SEC Form 4)
- Director Pamukcu Rifat was granted 3,135 shares, increasing direct ownership by 58% to 8,581 units (SEC Form 4)
- Director Seizinger Bernd R. was granted 3,135 shares, increasing direct ownership by 7% to 48,910 units (SEC Form 4)
- Aprea Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders